{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:46Z","timestamp":1777453066610,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacokinetic (PK) changes can affect antiretroviral (ARV) systemic exposure for critically ill patients living with HIV (CI-PLWH). Studies to guide ARV adjustments in this population are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A PK analysis was conducted in a 44-year-old CI-PLWH who presented for a heart and lung transplant on veno-arterial extracorporeal membrane oxygenation (VA ECMO). Home ARV therapy (ART) of co-formulated abacavir\/lamivudine\/dolutegravir (ABC\/3TC\/DTG) was continued. ARV serum concentrations were obtained during and after VA ECMO. Two blood levels were drawn at 1 h, for maximum serum concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ) and a serum trough (C\n                      <jats:sub>t<\/jats:sub>\n                      ). ARVs were given as a single tablet crushed via nasogastric tube.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Area under the concentration\u2013time curve (AUC\n                      <jats:sub>0\u2013t<\/jats:sub>\n                      ) was calculated using non-compartmental analysis. C\n                      <jats:sub>max<\/jats:sub>\n                      and AUC\n                      <jats:sub>0\u2013t<\/jats:sub>\n                      were higher during VA ECMO compared with post-decannulation. The C\n                      <jats:sub>max<\/jats:sub>\n                      of ABC was &gt;2.5-fold higher than the mean in the reference. C\n                      <jats:sub>max<\/jats:sub>\n                      and C\n                      <jats:sub>t<\/jats:sub>\n                      post VA ECMO were within range of referenced literature for all ARVs. C\n                      <jats:sub>max<\/jats:sub>\n                      and AUC\n                      <jats:sub>0\u2013t<\/jats:sub>\n                      of DTG post VA ECMO was approximately four- to fivefold lower than referenced literature. HIV virological suppression was maintained throughout the hospitalization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ART adjustments would not be required for this patient. Additional studies are needed to assess effects of VA ECMO and crushed tube administration of ARVs in CI-PLWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3355","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T04:13:48Z","timestamp":1588047228000},"page":"115-119","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Veno-Arterial Extracorporeal Oxygenation and Nasogastric Tube Administration on the Pharmacokinetic Profile of Abacavir, Lamivudine and Dolutegravir: A Case Report"],"prefix":"10.1177","volume":"25","author":[{"given":"Alison L","family":"Blackman","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Boston Medical Center, Boston, MA, USA"},{"name":"Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S","family":"Devanathan","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha Sheth","family":"Pandit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"bibr1-IMP3355","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2011.05.001"},{"key":"bibr2-IMP3355","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12636"},{"key":"bibr3-IMP3355","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1835"},{"key":"bibr4-IMP3355","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328328f79d"},{"key":"bibr5-IMP3355","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.169"},{"key":"bibr6-IMP3355","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1882"},{"key":"bibr7-IMP3355","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.09.154"},{"key":"bibr8-IMP3355","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2017.03.010"},{"key":"bibr9-IMP3355","first-page":"126","volume":"19","author":"Nyberg C.R.","year":"2011","journal-title":"Top Antivir Med"},{"key":"bibr10-IMP3355","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-019-00757-8"},{"key":"bibr11-IMP3355","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01000-08"},{"key":"bibr12-IMP3355","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140090-00005"},{"key":"bibr13-IMP3355","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1dd9"},{"key":"bibr14-IMP3355","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70290-0"},{"key":"bibr15-IMP3355","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky191"},{"key":"bibr16-IMP3355","doi-asserted-by":"publisher","DOI":"10.1177\/2325957417692678"},{"key":"bibr17-IMP3355","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1960"},{"key":"bibr18-IMP3355","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418797847"},{"key":"bibr19-IMP3355","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160102"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3851\/IMP3355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:53Z","timestamp":1777380773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.3851\/IMP3355"],"URL":"https:\/\/doi.org\/10.3851\/imp3355","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}